BIB vs PBE

ProShares Ultra NASDAQ Biotechnology against Invesco Biotechnology & Genome ETF: cost, size, returns, what they hold and how much of it is the same.

Overlap by weight
34%
25 shared positions
Fee gap
36 bp
PBE is cheaper
1-year return gap
17.5 pts
BIB is ahead
Larger fund
PBE
$422M

Side by side

BIBPBE
FundProShares Ultra NASDAQ BiotechnologyInvesco Biotechnology & Genome ETF
IssuerProSharesInvesco
CategoryLeveraged EquityBiotech & Health Innovation
Expense ratio0.95%0.59%
Assets$48M$422M
Average daily dollar volume$937K$1.8M
ListedApr 6, 2010Jun 23, 2005
FrenzyCap score4349
1-month return−4.9%−3.3%
3-month return−8.8%−0.6%
Year to date+35.9%+16.8%
1-year return+41.2%+23.7%
30-day volatility61.2%27.8%
Worst drawdown, 1 year−17.9%−11.8%
Trailing 12-month yield0.21%1.39%
Holdings25332
Top 10 weight155.7%50.1%
Look-through P/E—72.0
Holdings vs fair value+8.0%+14.3%
Holdings above 200-day average80%80%
Net flow, latest 3 reported months+$1.5M thru Aug 2026+$5.9M thru Jul 2026
30-day implied volatility56.9%29.5%
Holdings as ofas of Nov 18, 2026issuer dataas of Nov 17, 2026issuer data

Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.

Largest shared holdings

35% of BIB · 85% of PBE
HoldingBIBPBE
GILD6.21%5.89%
AMGN5.55%5.33%
VRTX5.29%4.97%
REGN4.21%5.92%
MRNA3.46%3.66%
BIIB1.63%5.85%
ILMN1.40%4.64%
RPRX1.34%5.72%
UTHR1.09%3.16%
INCY1.05%2.58%
EXEL0.74%3.39%
NBIX0.73%3.04%
BMRN0.52%2.48%
HALO0.48%2.47%
PTGX0.36%2.33%
PTCT0.22%2.31%
ACAD0.14%1.68%
VCEL0.13%3.76%
VCYT0.09%1.54%
BCRX0.08%2.14%
SRPT0.07%2.19%
ANAB0.06%2.19%
NVAX0.06%2.37%
COLL0.04%2.61%
ARDX0.03%2.36%

Sector mix of the stock holdings

SectorBIBPBEGap
Health Care63.3%93.2%−30.0%
Technology2.2%4.6%−2.4%
Materials0.0%0.0%+0.0%

More: full overlap table · BIB holdings · PBE holdings

Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.